Appendix O: Clinical evidence – forest plots and summary ROC curves for all studies

| studi | es 1 | |
|-----------------|----------------------------------------------------------------------------------------------------------------------------|-----|
| O.1 Asse | ssment tools | 6 |
| 0.1.1 | Tools for the recognition of mental health problems | . 6 |
| O.1.2 | Risk assessment tools | 15 |
| O.1.2.1 | VISCI for assessment of risk of sexual re-offending | 15 |
| O.2 Inter | ventions for staff training | 16 |
| O.2.1 train | Organisational linkage intervention (OLI) plus Medication-assisted ing (MAT) vs Training alone at post-treatment | 16 |
| O.3 Inter | ventions for promoting mental health and well being | 17 |
| O.3.1 wom | Parent training for parent-child attachment versus treatment as usual for en with sub-threshold symptoms at post-treatment | 17 |
| O.3.2 cont | Yoga for promoting mental health and wellbeing versus waiting list | 20 |
| O.3.3 as us | Meditation for promoting mental health and well-being versus treatment sual | 21 |
| O.3.4 being | Physical exercise programmes for promoting mental health and well-g versus exercise as usual at post-treatment | 22 |
| O.4 Inter | ventions for substance misuse | 23 |
| 0.4.1 | Psychological interventions | 23 |
| 0.4.1.1 | CBT versus active intervention | 23 |
| 0.4.1.2 | CBT versus wait-list control | 25 |
| O.4.1.3 | ACT versus CBT | 25 |
| 0.4.1.4 | ACT versus waitlist | 26 |
| O.4.1.5 | lem:mindfulness-based relapse prevention (MBRP) versus active intervention . | 27 |
| O.4.1.6 | Contingency management versus active intervention at post-treatment | 28 |
| O.4.1.7 | Contingency management versus control at post-treatment | 29 |
| O.4.1.8 | Motivational enhancement therapy versus active intervention | 29 |
| O.4.1.9 usua | Motivational interviewing or feedback versus control or treatment as | 31 |
| O.4.1.10 | Group counselling versus treatment as usual | 33 |
| 0.4.1.11 | Self-help versus control | 34 |
| 0.4.2 | Pharmacological interventions | 35 |
| O.4.2.1 | Naloxone versus placebo | 35 |
| 0.4.2.2 | Naltrexone versus active intervention | 35 |
| O.4.2.3 | Methadone versus waitlist control | 39 |
| 0424 | Alpha-adrenergic agonists versus opioid maintenance | 41 |

| 0.4.2.5 | Opioid substitution versus active intervention | . 42 |
|------------------|------------------------------------------------------------------------------------------------|------|
| O.4.3 | Combined psychological and pharmacological interventions | . 44 |
| O.4.3.1 thera | Antidepressants plus psychological therapy versus psychological apy alone for substance misuse | . 44 |
| O.4.4 | Support and educational interventions | . 44 |
| O.4.4.1 | Psychoeducation versus control or treatment as usual | . 44 |
| O.4.4.2 | Employment workshop versus control or treatment as usual | . 45 |
| O.4.5 | Physical interventions | . 45 |
| O.4.5.1 | Acupuncture versus active intervention | . 45 |
| O.5 Inter | ventions for 'other' mental health disorders | . 46 |
| O.5.1 | Depression | . 46 |
| O.5.1.1 | Psychotherapy vs PSYCHOED | . 46 |
| O.5.1.2 | Group therapy vs Individual therapy | . 46 |
| O.5.1.3 | Arts-based Therapy vs TAU | . 47 |
| O.5.2 | Vulnerable inmates with suicidal risks | . 48 |
| O.5.2.1 | Social problem solving group vs No treatment control | . 48 |
| O.5.3 | Anxiety disorder | . 49 |
| O.5.3.1 | Self-help therapy vs Wait-list control | . 49 |
| O.5.4 | PTSD | . 50 |
| O.5.4.1 | Psychotherapy vs Control | . 50 |
| O.5.4.2 | TIR vs Wait-list control | . 50 |
| O.5.4.3 | TARGET vs SGT | . 51 |
| O.5.4.4 | Focused group therapy vs Wait-list control | . 52 |
| O.5.4.5 | Group Therapy vs No contact control | . 52 |
| O.5.5 | ADHD | . 53 |
| O.5.5.1 | MPH vs Placebo | . 53 |
| O.5.6 | Antisocial personality disorders | . 53 |
| O.5.6.1 | Tiagabine vs Placebo | . 53 |
| O.5.7 | Severe Mental Illness | . 54 |
| O.5.7.1 | IM Paliperidone vs Oral Antipsychotics for schizophrenia | . 54 |
| O.5.7.2 | The Citizenship Project vs TAU | . 54 |
| O.5.7.3 | IPS vs Peer Support | . 55 |
| O.5.8 | Uncategorized mental health disorders | . 56 |
| O.5.8.1 | Parenting from inside (PFI) vs TAU | . 56 |
| O.5.8.2 | Music therapy vs Standard care for mental health disorders | . 56 |
| O.5.8.3 | Music therapy vs Wait-list control for antisocial personality disorders | . 57 |
| O.6 Inter | ventions for paraphilic disorders | |
| O.6.1 | MPA + psych intervention vs psych intervention only at post-treatment | . 58 |
| O.6.2 | MPA only vs psych intervention only at post-treatment | . 59 |

| | Psychoeducational interventions, principally CBT-informed hoeducation (including SOTP) versus treatment as usual, no treatment or ist control for paraphilic disorders | 59 |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| O.6.4 diso | Reintegration programmes versus treatment as usual for paraphilic rders | 63 |
| O.6.5 | Imaginal desensitization plus MPA versus MPA for paraphilic disorders | 65 |
| O.6.6 diso | Imaginal desensitization versus covert sensitization for paraphilic | 65 |
| O.7 Serv | ice delivery models | 66 |
| O.7.1 | Street Triage (Before versus After) | 66 |
| O.7.2 | Diversion Services | 67 |
| O.7.2.1 | Before and After Diversion Services | 67 |
| O.7.2.2 | Assessment versus No assessment at court | 67 |
| O.7.2.3 | Court Diversion vs Community Diversion | 68 |
| O.7.3 follo | Patient Navigation Intervention versus facilitated enrolment (at 26-weeks w-up) | 69 |
| O.7.4 | Neighbourhood outreach (Before versus After) | 69 |
| O.7.5 | Drug Rehabilitation Program versus TAU | 70 |
| O.7.6 | Case management | 70 |
| O.7.6.1 | Case management vs TAU for substance misuse disorders | 70 |
| O.7.6.2 | Case management vs active intervention for substance misuse disorders . | 75 |
| O.7.6.3 | Assertive Community Treatment vs TAU for substance misuse disorders | 77 |
| O.7.6.4 | Case management vs TAU for mental health disorders other than | |
| | tance misuse | |
| O.7.7 | Drug court | |
| O.7.7.1 | Drug court vs TAU | |
| O.7.7.2 | Drug court vs active intervention | |
| O.7.8 | Opioid substitution therapy | 81 |
| O.7.8.1 | Opioid substitution therapy + case management vs active intervention | 81 |
| O.7.9 | Automated Telephony (AT) with feedback versus AT alone | |
| O.7.10 | IDDT versus TAU | 85 |
| O.7.11 | Housing First versus TAU | 85 |
| O.7.12 | TIMA versus TAU | 86 |
| O.7.13 | Service Brokerage Intervention versus TAU | 86 |
| O.7.14 | Therapeutic communities | 87 |
| O.7.14.1 | Therapeutic community versus waitlist control | 87 |
| O.7.14.2 | Therapeutic community versus active intervention | 87 |
| O.7.14.3 | Modified therapeutic community versus psychoeducation | 90 |
| | Enhanced therapeutic community versus standard therapeutic munity | 91 |
| | Gender-responsive therapeutic community versus standard therapeutic munity | 92 |
| | Gender-specific therapeutic community versus psychoeducation | |

O.7.14.7 Re-entry modified therapeutic community versus treatment as usual........ 97

Abbreviations

ABCS Abel and Becker Cognitions Scale
ACT acceptance and commitment therapy
APQ Alabama Parenting Questionnaire

ASI-6 Addiction Severity Index-6
BDI Beck Depression Inventory
BSI Brief Symptom Inventory
CBT cognitive behavioural therapy

CES-D Centre for Epidemiological Studies Depression scale

CIB Coding Interactive Behaviour scales

CJS criminal justice system

CMHS (-M/W) Correctional Mental Health Screen (for Men/Women)

ECBI Eyberg Child Behaviour Inventory

HELP-PC

MORS Mother's Object Relations Scale
MPA medroxyprogesterone acetate
PANAS Positive and Negative Affect Scale
PDI Parent Development Interview

PSS Perceived Stress Scale RDS Referral Decision Scale

ROC receiver operating characteristic
RCT randomised controlled trial
SCL-90-R Symptom Checklist-90-Revised
SIP Short Inventory of Problems
SOR sex offender's register

SOTP sex offender treatment programme

VISCI Viennese Instrument for Suicidality in Correctional Institutions

0.1 Assessment tools

0.1.1 Tools for the recognition of mental health problems

Figure 1: Sensitivity and specificity of index tests for the recognition of depression




Figure 2: Summary ROC curves for the index tests for depression




Figure 3: Sensitivity and specificity of the RDS for the recognition of bipolar disorder




Figure 4: Summary ROC curves for the RDS for bipolar disorder




Figure 5: Sensitivity and specificity of index tests for the recognition of affective disorder

Correctional Mental Health Screen for Men (CMHS-M) - Cut-off 7 - All Men Study TP FP FN TN Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI) 0.83 [0.63, 0.95] Ford 2007 4 129 0.73 [0.66, 0.79] Correctional Mental Health Screen for Men (CMHS-M) - Cut-off 7 - Caucasian Men Study TP FP FN TN Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI) 0.94 [0.73, 1.00] Ford 2007 17 18 1 62 0.78 [0.67, 0.86] Correctional Mental Health Screen for Men (CMHS-M) - Cut-off 7 - Black Men TP FP FN TN Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI) Ford 2007 3 20 0 46 1.00 [0.29, 1.00] 0.70 [0.57, 0.80] Correctional Mental Health Screen for Women (CMHS-W) - Cut-off 5 Sensitivity (95% CI) TP FP FN TN Sensitivity (95% CI) Specificity (95% CI) Specificity (95% CI) Ford 2007 0.73 [0.54, 0.87] 0.70 [0.58, 0.81]

Figure 6: Summary ROC curves for the index tests for affective disorder




Figure 7: Sensitivity and specificity of the HELP-PC (cut-off 1) for the recognition of learning disabilities



Figure 8: Summary ROC curve for the HELP-PC for learning disabilities




Figure 9: Sensitivity and specificity of RDS: schizophrenia subscale (cut-off 1) for the recognition of schizophrenia



Figure 10: Summary ROC curve for the RDS: schizophrenia subscale for schizophrenia




Figure 11: Sensitivity and specificity of the HELP-PC (cut-off not reported) for the recognition of psychosis






Figure 12: Summary ROC curve for the HELP-PC for psychosis

Figure 13: Sensitivity and specificity of the CMHS-W (cut-off 4) for the recognition of Axis-I or Axis-II disorder




Figure 14: Summary of ROC curve for the CMHS-W for Axis-I or Axis-II disorder




Figure 15: Sensitivity and specificity of index tests for the recognition of Axis-I or Axis-II disorder excluding Anti-Social Personality Disorder

Correctional Mental Health Screen for Men (CMHS-M) - Cut-off 5 TP FP FN TN Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI) Study 0.78 [0.66, 0.88] Ford 2009 37 13 9 47 0.80 [0.66, 0.91] Correctional Mental Health Screen for Men (CMHS-M) - Cut-off 6 TP FP FN TN Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI) Ford 2007 0.74 [0.62, 0.84] 0.75 [0.67, 0.82] 51 33 18 99 0.70 [0.54, 0.82] Ford 2009 32 10 14 50 0.83 [0.71, 0.92] 0 0.2 0.4 0.6 0.8 1 Correctional Mental Health Screen for Men (CMHS-M) - Cut off 6 - Caucasian Men Study TP FP FN TN Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI) Ford 2007 27 14 6 50 0.82 [0.65, 0.93] 0.78 [0.66, 0.87] 0 0.2 0.4 0.6 0.8 1 Correctional Mental Health Screen for Men (CMHS-M) - Cut-off 6 - Black Men TP FP FN TN Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI) Study Ford 2007 16 14 4 35 0.80 [0.56, 0.94] 0.71 [0.57, 0.83] Correctional Mental Health Screen for Women (CMHS-W) - Cut-off 4 Study TP FP FN TN Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI) Ford 2009 45 11 16 28 0.74 [0.61, 0.84] 0.72 [0.55, 0.85] 0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1 Referral Decision Scale (RDS) - Cut-off 3 TP FP FN TN Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI) 0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1 Ford 2007 11 2 4 10 0.73 [0.45, 0.92] 0.83 [0.52, 0.98]

Figure 16: Summary ROC curves for the index tests for Axis-I or Axis-II disorder excluding Anti-Social Personality Disorder





Figure 17: Sensitivity and specificity of the current prison reception health screen (cut-off 1) for the recognition of serious mental illness



Figure 18: Summary of ROC curve for the current prison reception health screen for serious mental illness



O.1.2 Risk assessment tools

O.1.2.1 VISCI for assessment of risk of sexual re-offending

Figure 19: VISCI using a cut-off of 3.38



O.2 Interventions for staff training

O.2.1 Organisational linkage intervention (OLI) plus Medication-assisted training (MAT) vs Training alone at post-treatment

Figure 20 Familiarity with medication: Methadone

| | OLI plus training Training alone | | | | | | | Mean Difference | Mean Difference | | | | |
|----------------------------------------------------------------------------|----------------------------------|------|-------|------|------|-------|--------|--------------------|-----------------|------------------------------|------------------|--------------------|---|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Fixed, 95% CI | | IV, Fixed | d, 95% CI | | |
| Friedmann 2015 | 0.4 | 1.42 | 383 | 0.26 | 1.01 | 464 | 100.0% | 0.14 [-0.03, 0.31] | | | - | | |
| Total (95% CI) | | | 383 | | | 464 | 100.0% | 0.14 [-0.03, 0.31] | | | • | | |
| Heterogeneity: Not applicable Test for overall effect: Z = 1.62 (P = 0.11) | | | | | | | | | -2 | -1 Favours training alone | 0 Favours OLI | l plus training | 2 |

Figure 21 Referral knowledge: Methadone

| OLI plus training | | | | Train | ing ald | one | | Mean Difference | Mean Difference | | | | |
|-------------------------------------------------------------------------------|------|------|-------|-------|---------|-------|--------|--------------------|-----------------|--------------------------------|-------------------|------------------------|---|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Fixed, 95% CI | | IV, Fixe | d, 95% CI | | |
| Friedmann 2015 | 0.28 | 0.99 | 383 | 0.24 | 1.23 | 464 | 100.0% | 0.04 [-0.11, 0.19] | | _ | | | |
| Total (95% CI) | | | 383 | | | 464 | 100.0% | 0.04 [-0.11, 0.19] | | - | • | | |
| Heterogeneity: Not applicable Test for overall effect: Z = 0.52 (P = 0.60) | | | | | | | | | ! | -0.5 Favours training alone | 0 (Favours Ol |).5 LI plus trainin | 1 |

Figure 22 Intent to refer clients to MAT: Methadone




Figure 23 Overall perception and knowledge: Methadone




Figure 24 Familiarity with the medication: Buprenorphine




Figure 25 Referral knowledge: Buprenorphine





Figure 26 Intent to refer clients to MAT: Buprenorphine

| OLI plus training T | | | | Train | ing ald | one | | Mean Difference | Mean Difference | | | | |
|-------------------------------------------------|------|------|-------|-------|---------|-------|--------|--------------------|--------------------------------------------------------------|--|--|--|--|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Fixed, 95% CI | IV, Fixed, 95% CI | | | | |
| Friedmann 2015 | 0.3 | 1.11 | 383 | 0.15 | 1.35 | 464 | 100.0% | 0.15 [-0.02, 0.32] | | | | | |
| Total (95% CI) | | | 383 | | | 464 | 100.0% | 0.15 [-0.02, 0.32] | • | | | | |
| Heterogeneity: Not a Test for overall effect | | | 08) | | | | | | -2 -1 0 1 2 Favours training alone Favours OLA plus training | | | | |

Figure 27 Overall perception and knowledge: Buprenorphine



Note – The scores ranged from 1 (strongly disagree) to 5 (strongly agree).

O.3 Interventions for promoting mental health and well being

O.3.1 Parent training for parent-child attachment versus treatment as usual for women with sub-threshold symptoms at post-treatment

Figure 28: Mean symptoms of depression as measured by the Center for Epidemiological Studies Depression Scale (CES-D)

| | Parent | t train | ing | | TAU | | | Std. Mean Difference | Std. Mean Difference |
|---------------------------------------------------|--------|---------|-------|------|------|-------|--------|----------------------|-------------------------------------------------|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI |
| Sleed 2013 | 13.6 | 9.4 | 62 | 15.3 | 11.8 | 53 | 100.0% | -0.16 [-0.53, 0.21] | - |
| Total (95% CI) | | | 62 | | | 53 | 100.0% | -0.16 [-0.53, 0.21] | → |
| Heterogeneity. Not ap Test for overall effect: | | 5 (P = | 0.39) | | | | | | -4 -2 0 2 4 Favours parent training Favours TAU |

Figure 29: Number of participants with symptoms of depression (CES-D=>16)




Figure 30: Mother-child attachment/interaction (after 4 week treatment): mean scores on the Reflective Functioning subscale of the Parent Development Interview (PDI)




Figure 31: Mother-child attachment/interaction (after 4 week treatment): mean scores for dyadic attunement based on behavioural observation of mother-

infant interaction during free-play coded using Coding Interactive Behaviour (CIB) scales




Figure 32: Maternal perceptions of child (after 4 week treatment): mean scores for positive perceptions of the infant as measured by the Mother's Object Relations Scale (MORS), Warmth subscale




Figure 33: Maternal perceptions of child (after 4 week treatment): mean scores for negative perceptions of the infant as measured by the MORS, Invasion subscale




Figure 34: Maternal perceptions of child (after 30 week treatment): mean scores for parental reports of the intensity of children's problem behaviour as measured by the Eyberg Child Behavior Inventory (ECBI)




Figure 35: Maternal perceptions of child (after 30 week treatment): mean scores for the extent to which child behaviour is a problem for parents as measured by the ECBI




Figure 36: Maternal perceptions of child (after 30 week treatment): mean scores for maternal perceptions of their involvement with their child as measured by the Alabama Parenting Questionnaire (APQ), Involvement subscale




Figure 37: Maternal perceptions of child (after 30 week treatment): mean scores for maternal perceptions of their positive parenting as measured by the APQ, Positive parenting subscale




Figure 38: Maternal perceptions of child (after 30 week treatment): mean scores for maternal perceptions of their poor monitoring/supervision as measured by the APQ, Poor monitoring/supervision subscale

| | parer | nt training | | | TAU | | | Std. Mean Difference | Std. Mean Difference | | | | |
|-------------------------------------------------|-----------|-------------|-------|-------|------|-------|--------|----------------------|----------------------|--------------------|---------------|--------------|---|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | | IV, Ra | ndom, 95 | % CI | |
| Menting 2014 | 11.202208 | 2.246847 | 77 | 10.48 | 2.04 | 25 | 100.0% | 0.33 [-0.13, 0.78] | | | - | | |
| Total (95% CI) | | | 77 | | | 25 | 100.0% | 0.33 [-0.13, 0.78] | | | • | | |
| Heterogeneity: Not a Test for overall effect | • | 0.16) | | | | | | | -4 Favours p | -2 arent traini | 0 ng Favoi | 2 urs TAU | 4 |

Figure 39: Maternal perceptions of child (after 30 week treatment): mean scores for maternal perceptions of their inconsistent discipline as measured by the APQ, Inconsistent discipline subscale




Figure 40: Maternal perceptions of child (after 30 week treatment): mean scores for maternal perceptions of their corporal punishment as measured by the APQ, Corporal punishment subscale




Figure 41: Drop out before the post-intervention assessment

| | parent tra | ining | TAU | J | | Risk Ratio | Risk Ratio | | | | |
|---------------------------------------------------|------------|-------|--------|---------|----------------|---------------------|-----------------------------------------------------|--|--|--|--|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | M-H, Random, 95% CI | | | | |
| Menting 2014 | 28 | 86 | 9 | 27 | 39.2% | 0.98 [0.53, 1.80] | | | | | |
| Sleed 2013 | 26 | 96 | 22 | 99 | 60.8% | 1.22 [0.74, 2.00] | - | | | | |
| Total (95% CI) | | 182 | | 126 | 100.0% | 1.12 [0.76, 1.64] | * | | | | |
| Total events | 54 | | 31 | | | | | | | | |
| Heterogeneity: Tau² = Test for overall effect: | | | | P = 0.5 | (8); $I^2 = 0$ | % | 0.01 0.1 10 100 Favours parent training Favours TAU | | | | |

O.3.2 Yoga for promoting mental health and wellbeing versus waiting list control

Figure 42: Positive and negative affect (after 10 week treatment): mean scores of positive affect as measured by the Positive and Negative Affect Scale (PANAS)




Figure 43: Positive and negative affect (after 10 week treatment): mean scores of negative affect as measured by the PANAS




Figure 44: Stress (after 10 week treatment): mean scores on the Perceived Stress Scale (PSS)




Figure 45: Psychological distress (after 10 week treatment): mean scores on the Brief Symptom Inventory (BSI)





Figure 46: Drop-out (after 10 week treatment): number of participants who dropped out before the post-intervention assessment



O.3.3 Meditation for promoting mental health and well-being versus treatment as usual

Figure 47: Desire to throw things/hit people (after 7 week treatment): mean scores on study-specific measure within past month




Figure 48 Being bothered by nail biting (after 7 week treatment): mean scores on study-specific measure within past month




Figure 49: Feelings of guilt (after 7 week treatment): mean scores on study-specific measure within past month

| Study or Subgroup | Std. Mean Difference | SE | meditation Total | TAU Total | Weight | Std. Mean Difference IV, Random, 95% CI | 5td. Mean Difference IV, Random, 95% CI |
|--------------------------------------------------|------------------------------------|----------|---------------------|--------------|--------|--------------------------------------------|--------------------------------------------|
| Sumter 2009 | -0.41727854 | 0.352082 | 17 | 16 | 100.0% | -0.42 [-1.11, 0.27] | |
| Total (95% CI) | | | 17 | 16 | 100.0% | -0.42 [-1.11, 0.27] | • |
| Heterogeneity: Not as Test for overall effect | oplicable : Z = 1.19 (P = 0.24) | | | | | | -4 -2 2 4 Favours meditation Favours TAU |

Figure 50 Feelings of hopelessness (after 7 week treatment): mean scores on studyspecific measure within past month





Figure 51: Being bothered by sleep difficulties (after 7 week treatment): mean scores on study-specific measure within past month



O.3.4 Physical exercise programmes for promoting mental health and well-being versus exercise as usual at post-treatment

Figure 52: Change in Symptom Checklist-90-Revised (SCL-90-R) Global Severity Index (GSI)




Figure 53: Change in Symptom Checklist-90-Revised (SCL-90-R) Positive Symptom Total (PST)





Figure 54: Change in Symptom Checklist-90-Revised (SCL-90-R) Positive Symptom Distress Index (PSDI)



O.4 Interventions for substance misuse

O.4.1 Psychological interventions

0.4.1.1 CBT versus active intervention

Figure 55: Days using cannabis during treatment




Figure 56: Days with a positive urine test during treatment




Figure 57: Days with a positive breathalyser test during treatment




Figure 58: Days abstinent during treatment




Figure 59: Addiction Severity Index (ASI-6): alcohol composite score at 26-38 weeks follow-up




Figure 60: Addiction Severity Index (ASI-6): drug composite score at 26-38 weeks follow-up

| | | CBT | | 12-step | ргодгаг | nme | | Mean Difference | Mean Difference | | | |
|--------------------------------------------------|------|------|-------|---------|---------|-------|--------|---------------------|----------------------------------------------|---|--|--|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | I IV, Random, 95% CI | | | |
| Zlotnick 2009 | 0.16 | 0.14 | 23 | 0.18 | 0.11 | 21 | 100.0% | -0.02 [-0.09, 0.05] | ij | | | |
| Total (95% CI) | | | 23 | | | 21 | 100.0% | -0.02 [-0.09, 0.05] | 1 | | | |
| Heterogeneity: Not ap Test for overall effect | | | 0.60) | | | | | | -1 -0.5 0 0.5 Favours CBT Favours 12-step | 1 | | |

Figure 61: Weeks abstinent (3 month follow-up) at 26-38 weeks follow-up





Figure 62: Re-incarceration at 26-38 weeks follow-up



0.4.1.2 CBT versus wait-list control

Figure 63: Addiction Severity Index (ASI-6): alcohol composite score at posttreatment




Figure 64: Addiction Severity Index (ASI-6): drug composite score at posttreatment





Figure 65: Abstinent in previous 3 months (6 month follow-up)



O.4.1.3 ACT versus CBT

Figure 66: Addiction Severity Index (ASI-6): alcohol composite score at posttreatment




Figure 67: Addiction Severity Index (ASI-6): drug composite score at posttreatment





Figure 68: Abstinent from drugs in previous 3 months at post-treatment



0.4.1.4 ACT versus waitlist

Figure 69: Addiction Severity Index (ASI-6): alcohol composite score at 42 weeks follow-up





Figure 70: Addiction Severity Index (ASI-6): drug composite score at 42 weeks follow-up

| 10110 | ,,, u | • | | | | | | | | |
|-----------------------------------|----------|----------|---------|----------|---------|----------------------|----------------------|----------------------|---------------------------------------------------|-------------|
| | | w | aitlist | | | Std. Mean Difference | Std. Mean Difference | | | |
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI | |
| Villagra Lanza 2013 | 0.4 | 0.55 | 16 | 0.44 | 0.38 | 11 | 52.2% | -0.08 [-0.85, 0.69] | - ■ | |
| Villagra Lanza 2014 | 0.4 | 0.05 | 14 | 0.44 | 0.04 | 11 | 47.8% | -0.84 [-1.67, -0.01] | - | |
| Total (95% CI) | | | 30 | | | 22 | 100.0% | -0.44 [-1.19, 0.30] | • | |
| Heterogeneity: Tau ² = | 0.12; Ch | ni² = 1. | 75, df= | 1 (P = I | 0.19);1 | $l^2 = 439$ | 6 | | - 1 | |
| Test for overall effect: | Z = 1.16 | (P = 0) | .24) | | | | | | -4 -2 U 2 Favours ACT Favours waitlis | t 4 |

Figure 71: Abstinent from drugs in previous 3 months at 42 weeks follow-up



0.4.1.5 Mindfulness-based relapse prevention (MBRP) versus active intervention

Figure 72: Drug-use days at post-treatment

| _ | I | ИBRР | | Relapse p | revention | (TAU) | | Mean Difference | | Mean | Differer | ice | |
|-------------------|------|------|-------|-----------|-----------|-------|--------|---------------------|----|-------------|----------|----------|---|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | | IV, Ran | dom, 95 | % CI | |
| Witkiewitz 2014 | 0.04 | 0.19 | 28 | 0.5 | 1.82 | 26 | | -0.46 [-1.16, 0.24] | | | + | | |
| | | | | | | | | | -4 | -2 | <u> </u> | 2 | 4 |
| | | | | | | | | | | Favoure MRR | P Favo | ure TALL | |

Figure 73: Short Inventory of Problems (SIP) follow-up at post-treatment


| | N | IBRP | | Relapse p | revention (| TAU) | | Mean Difference | | Me | ean Differen | ce | |
|-------------------|------|------|-------|-----------|-------------|-------|--------|----------------------|-----|-----------|--------------|----------|----|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | | IV, | Random, 95 | % CI | |
| Witkiewitz 2014 | 14.6 | 16.5 | 28 | 21.9 | 15.4 | 26 | | -7.30 [-15.81, 1.21] | + | | | | |
| | | | | | | | | | -10 | -5 | Ö | 5 | 10 |
| | | | | | | | | | | Favours N | IBRP Favo | ure TALL | |

Figure 74: Addiction Severity Index (ASI-6) at post-treatment

| igui e 14. | Au | uici | IUII | Severi | .y IIIu | ᅜᄼᅜ | 31-0 <i>)</i> | ai posi-ii eai | IIIGIIL |
|-------------------------|----------|-------------|---------|---------------|-----------|-------|---------------|----------------------|--------------------------|
| _ | N | IBRP | | Relapse p | revention | (TAU) | | Mean Difference | Mean Difference |
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI |
| .3.1 Family-social c | omposit | e scor | e | | | | | | |
| /itkiewitz 2014 | 0.13 | 0.16 | 28 | 0.14 | 0.12 | 26 | 100.0% | -0.01 [-0.09, 0.07] | |
| ubtotal (95% CI) | | | 28 | | | 26 | 100.0% | -0.01 [-0.09, 0.07] | |
| eterogeneity: Not ap | plicable | ! | | | | | | | |
| est for overall effect: | Z = 0.26 | 6 (P = 0 |).79) | | | | | | |
| .3.2 Legal composit | te score | | | | | | | | |
| Vitkiewitz 2014 | 0.04 | 0.12 | 28 | 0.35 | 0.35 | 26 | 100.0% | -0.31 [-0.45, -0.17] | |
| ubtotal (95% CI) | | | 28 | | | 26 | 100.0% | -0.31 [-0.45, -0.17] | • |
| eterogeneity: Not ap | plicable | ! | | | | | | | |
| est for overall effect: | Z = 4.29 | 9 (P < 0 |).0001) |) | | | | | |
| .3.3 Medical compo | site sco | ге | | | | | | | |
| /itkiewitz 2014 | 0.12 | 0.25 | 28 | 0.32 | 0.36 | 26 | 100.0% | -0.20 [-0.37, -0.03] | |
| ubtotal (95% CI) | | | 28 | | | 26 | 100.0% | -0.20 [-0.37, -0.03] | • |
| eterogeneity: Not ap | plicable | ! | | | | | | | |
| est for overall effect: | Z = 2.35 | (P = 0 |).02) | | | | | | |
| .3.4 Psychiatric cor | nposite | score | | | | | | | |
| /itkiewitz 2014 | 0.23 | 0.17 | 28 | 0.34 | 0.24 | 26 | 100.0% | -0.11 [-0.22, 0.00] | |
| ubtotal (95% CI) | | | 28 | | | 26 | 100.0% | -0.11 [-0.22, 0.00] | • |
| eterogeneity: Not ap | plicable | ! | | | | | | | |
| est for overall effect: | Z = 1.93 | (P = 0 |).05) | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | -4 -2 0 2 4 |
| act for outgroup diff | foronoco | · Obiz | - 45 00 | 2 AF = 2 /D = | 0.000 12 | 00.50 | | | Favours MBRP Favours TAU |

Test for subgroup differences: Chi² = 15.36, df = 3 (P = 0.002), I² = 80.5%

0.4.1.6 Contingency management versus active intervention at post-treatment






Figure 76: Addiction Severity Index (ASI-6): marijuana composite score at posttreatment




Figure 77: Days cannabis use per month at post-treatment





Figure 78: Participants still in treatment at follow-up at post-treatment




Figure 79: Number of days in treatment at post-treatment



0.4.1.7 Contingency management versus control at post-treatment

Figure 80: Arrests for public drunkenness



0.4.1.8 Motivational enhancement therapy versus active intervention

Figure 81: Percentage of days abstinent from alcohol (self-report) at post-treatment




Figure 82: Percentage of days abstinent from alcohol and drugs at post-treatment




Figure 83: Drinks per drinking days at post-treatment




Figure 84: Percentage of days with cannabis use during treatment




Figure 85: Percentage of urine tests positive for cannabis use during treatment

MET other active intervention Std. Mean Difference Std. Mean Difference



Figure 86: Self-reported motivation to take steps to change substance abuse scores at post-treatment

| | ME + p | osycho | ed. | Psy | choed | 1. | | Mean Difference | | Mean D | fference | |
|-------------------|--------|--------|-------|------|-------|-------|--------|---------------------|-----|------------------|----------------|---------|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | | IV, Rando | m, 95% CI | |
| Easton 2000 | 25.1 | 10.4 | 18 | 21 | 13.2 | 9 | | 4.10 [-5.77, 13.97] | | . — | <u> </u> | |
| | | | | | | | | | -20 | -10 | 10 | 20 |
| | | | | | | | | | | Favours psychoed | Favours MF + n | sychoed |

O.4.1.9 Motivational interviewing or feedback versus control or treatment as usual

Figure 87: Self-reported drug use at post-treatment




Figure 88: Self-reported days with drug use in the past 30 days (10 month follow-up)





Figure 89: Urine test positive for drug use during study period at post-treatment








Figure 91: Days with illegal activity in the past 30 days (10 month follow-up)

| | | MI | | 1 | ΓAU | | | Std. Mean Difference | | Std. I | Aean Differ | ence | |
|-----------------------------------------|----------|----------|-------|------|-----|-------|--------|----------------------|-------------|-------------|-------------|-------------|---|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | | IV, F | andom, 95 | % CI | |
| Forsberg 2011 | 3.92 | 9.22 | 80 | 3.3 | 9 | 23 | 100.0% | 0.07 [-0.40, 0.53] | | | - | | |
| Total (95% CI) Heterogeneity: Not ap | plicable | ! | 80 | | | 23 | 100.0% | 0.07 [-0.40, 0.53] | | | <u> </u> | | |
| Test for overall effect: | Z = 0.28 |) (P = 0 | 0.78) | | | | | | -4 | Favou | rs MI Favo | urs TAU | 4 |

Figure 92: Drop-out from subsequent treatment (binge drinking group) at posttreatment




Figure 93: Drop-out from subsequent treatment (non-binge drinking group) at post-treatment




Figure 94: Number of subsequent treatment sessions attended (binge drinking group) at post-treatment

| _ | | MI | | No t | reatm | ent | | Mean Difference | Mean Difference |
|---------------------------------------------------|------|-------|--------|------|-------|-------|--------|---------------------|----------------------------------------------------|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Fixed, 95% CI | IV, Fixed, 95% CI |
| Crane 2015b | 14.6 | 10.08 | 10 | 3.44 | 5.77 | 9 | 100.0% | 11.16 [3.86, 18.46] | |
| Total (95% CI) | | | 10 | | | 9 | 100.0% | 11.16 [3.86, 18.46] | |
| Heterogeneity. Not ap Test for overall effect: | | | 0.003) | | | | | | -20 -10 0 10 20 Favours no treatment Favours MI |

Figure 95: Number of subsequent treatment sessions attended (non-binge drinking group) at post-treatment

| | | MI | | No | treatme | nt | | Mean Difference | Mean Difference |
|---------------------------------------------------|-------|------|-------|------|---------|-------|--------|---------------------|--------------------------------------------------|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Fixed, 95% CI | IV, Fixed, 95% CI |
| Crane 2015b | 11.35 | 8.45 | 20 | 13 | 10.86 | 15 | 100.0% | -1.65 [-8.28, 4.98] | |
| Total (95% CI) | | | 20 | | | 15 | 100.0% | -1.65 [-8.28, 4.98] | |
| Heterogeneity: Not ap Test for overall effect: | | | 0.63) | | | | | | -10 -5 0 5 10 Favours no treatment Favours MI |

Figure 96: Specialty addiction clinic attendance at post-treatment

| | Motivational fee | edback | No treat | ment | | Risk Ratio | RISK RATIO |
|---------------------------------------------------|------------------|--------|----------|-------|--------|--------------------|----------------------------------------------------------------|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI |
| Davis 2003 | 8 | 17 | 4 | 13 | 100.0% | 1.53 [0.59, 3.99] | |
| Total (95% CI) | | 17 | | 13 | 100.0% | 1.53 [0.59, 3.99] | |
| Total events | 8 | | 4 | | | | |
| Heterogeneity. Not ap Test for overall effect: | | 39) | | | | | 0.1 0.2 0.5 1 2 5 10 Favours no treatment Favours motivational |

0.4.1.10 Group counselling versus treatment as usual

Figure 97: Re-arrest (12 month follow-up)




Figure 98: Number of reconvictions (12 month follow-up)






Figure 99: Re-incarceration (12 month follow-up)


| J | | | | • | _ | | | | |
|-------------------------------------------------|---------------|---------|--------|-------|--------|---------------------|------------------------|---------------------|-----|
| | group coun | selling | contr | rol | | Risk Ratio | F | Risk Ratio | |
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | M-H, R | andom, 95% CI | |
| Annis 1979 | 24 | 85 | 14 | 43 | 100.0% | 0.87 [0.50, 1.50] | | - | |
| Total (95% CI) | | 85 | | 43 | 100.0% | 0.87 [0.50, 1.50] | | • | |
| Total events | 24 | | 14 | | | | | | |
| Heterogeneity: Not a Test for overall effect | | N 61) | | | | | 0.01 0.1 | 1 10 | 100 |
| 1001101 0101411 011001 | 2 - 0.01 (1 - | 0.017 | | | | | Favours group counsell | ing Favours control | |





O.4.1.11 Self-help versus control

Figure 102: Subsequent bookings (12 month follow-up)



O.4.2 Pharmacological interventions

O.4.2.1 Naloxone versus placebo

Figure 103: Discontinued medication at post-treatment


| | naloxo | one | place | bo | | Risk Ratio | Risk Ratio |
|---------------------------------------------------|--------|----------|--------|-------|--------|---------------------|----------------------------------------------------|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | M-H, Random, 95% CI |
| Hanlon 1977 | 16 | 55 | 8 | 42 | 100.0% | 1.53 [0.72, 3.23] | _ |
| Total (95% CI) | | 55 | | 42 | 100.0% | 1.53 [0.72, 3.23] | - |
| Total events | 16 | | 8 | | | | |
| Heterogeneity: Not ap Test for overall effect: | • | (P = 0.2 | 27) | | | | 0.01 0.1 1 10 100 Favours naloxone Favours placebo |

Figure 104: Number of urine test positive at post-treatment

| | naloxo | one | place | bo | | Risk Ratio | | Ris | sk Ratio | | |
|---------------------------------------------------|--------|----------|--------|-------|--------|---------------------|------|------------------------|-----------|---------------|-----|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | | M-H, Raı | ndom, 95% | CI | |
| Hanlon 1977 | 5 | 73 | 10 | 90 | 100.0% | 0.62 [0.22, 1.72] | | _ | | | |
| Total (95% CI) | | 73 | | 90 | 100.0% | 0.62 [0.22, 1.72] | | - | | | |
| Total events | 5 | | 10 | | | | | | | | |
| Heterogeneity: Not ap Test for overall effect: | • | (P = 0.3 | 86) | | | | 0.01 | 0.1 Favours naloxon | e Favours | 10 placebo | 100 |

O.4.2.2 Naltrexone versus active intervention

Figure 105: Retained in treatment at post-treatment






Figure 107: Cocaine use at post-treatment


Test for subgroup differences: Chi² = 1.27, df = 4 (P = 0.87), I^2 = 0%

| | naltrex | one | other active inter | vention | | Risk Ratio | | Risk | Ratio | | |
|-------------------------------------------------|---------|----------|--------------------|---------|--------|---------------------|------|---------------------------|------------------------|---|-----|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | | M-H, Rand | om, 95% CI | | |
| Coviello 2010 | 5 | 31 | 2 | 32 | 100.0% | 2.58 [0.54, 12.33] | | _ | | : | |
| Total (95% CI) | | 31 | | 32 | 100.0% | 2.58 [0.54, 12.33] | | - | | | |
| Total events | 5 | | 2 | | | | | | | | |
| Heterogeneity: Not a Test for overall effect | | (P = 0.2 | 3) | | | | 0.01 | 0.1 Favours naltrexone | 1 10 Favours other: | | 100 |

Favours naltrex. + couns. Favours counselling

Figure 108: Opioid use post-treatment

| | naltrexone | | • | | | | | | | | |
|---------------------------------------------------------------------------------------------------------|------------|-------|---------------------------|-------|------------|---------------------|------|----------------------------------------------|-------------|----|-----|
| | | | other active intervention | | Risk Ratio | | | Risk Ratio | | | |
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | | M-H, Random, 95% CI | | | |
| Coviello 2010 | 5 | 31 | 8 | 32 | 4.5% | 0.65 [0.24, 1.76] | | | | | |
| Lee 2016 | 66 | 153 | 99 | 155 | 95.5% | 0.68 [0.54, 0.84] | | | | | |
| Total (95% CI) | | 184 | | 187 | 100.0% | 0.67 [0.55, 0.83] | | | • | | |
| Total events | 71 | | 107 | | | | | | | | |
| Heterogeneity: Tau ² = 0.00; Chi ² = 0.01, df = 1 (P = 0.93); I ² = 0% | | | | | | | 0.01 | 01 | | 10 | 100 |
| Test for overall effect: Z = 3.65 (P = 0.0003) | | | | | | | | Favours naltrexone Favours other active int. | | | |






Figure 110: Days of drug use per month (6-month follow-up)




Figure 111: Re-incarceration at post-treatment

| • | naltrex | cone | other active interv | vention | | Risk Ratio | Risk Ratio |
|-----------------------------------|--------------|-------------------|-----------------------------|-------------------|------------------------|------------------------------------------------|----------------------------------------------|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | M-H, Random, 95% CI |
| 17.7.1 During treatm | ent | | | | | | |
| Cornish 1997 Subtotal (95% CI) | 9 | 34 34 | 9 | 17 17 | 20.1% 20.1 % | 0.50 [0.24, 1.02] 0.50 [0.24, 1.02] | • |
| Total events | 9 | | 9 | | | | |
| Heterogeneity: Not ap | pplicable | | | | | | |
| Test for overall effect: | : Z= 1.89 | (P = 0.0) | 6) | | | | |
| 17.7.2 Post-treatme | nt | | | | | | |
| Lee 2016 Subtotal (95% CI) | 35 | 153 153 | 45 | 155 155 | 71.2% 71.2% | 0.79 [0.54, 1.15] 0.79 [0.54, 1.15] | + |
| Total events | 35 | | 45 | | | | |
| Heterogeneity: Not ap | pplicable | | | | | | |
| Test for overall effect | : Z= 1.23 | (P = 0.2 | 2) | | | | |
| 17.7.3 6 month follow | w-up | | | | | | |
| Lobmaier 2010 | 5 | 23 | 5 | 21 | 8.7% | 0.91 [0.31, 2.71] | |
| Subtotal (95% CI) | | 23 | | 21 | 8.7% | 0.91 [0.31, 2.71] | |
| Total events | 5 | | 5 | | | | |
| Heterogeneity: Not ap | | | | | | | |
| Test for overall effect: | : Z= 0.16 | (P = 0.8 | 7) | | | | |
| Total (95% CI) | | 210 | | 193 | 100.0% | 0.73 [0.53, 1.00] | • |
| Total events | 49 | | 59 | | | | |
| Heterogeneity: Tau² = | | | | ² =0% | | | 0.01 0.1 1 10 1 |
| Test for overall effect: | : Z = 1.93 i | (P = 0.0) | 5) | | | | Favours naltrexone Favours other active int. |
| Test for subgroup dif | ferences: | $Chi^2 = 1$ | 1.39, $df = 2$ ($P = 0.50$ | 0), I² = 0% | | | vara riamanaria i arama anti datira ilit. |

Figure 112: Parole violations at post-treatment

| | naltrexone + psychosocia | | | | | Risk Ratio | Risk | Risk Ratio | | | |
|---------------------------------------------------|--------------------------|-------|--------|-------|--------|---------------------|---------------------------------------|------------------------------|-----|--|--|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | M-H, Rand | om, 95% CI | | | |
| Coviello 2010 | 2 | 31 | 9 | 32 | 100.0% | 0.23 [0.05, 0.98] | | | | | |
| Total (95% CI) | | 31 | | 32 | 100.0% | 0.23 [0.05, 0.98] | | | | | |
| Total events | 2 | | 9 | | | | | | | | |
| Heterogeneity: Not ap Test for overall effect: | • | | | | | | 0.01 0.1 Favours naltrex. + psych. | 1 10 Favours psychosocial | 100 | | |

Figure 113: Drug charges at post-treatment

| _ | osocial | psychos | ocial | | Risk Ratio | Risk Ratio | |
|--------------------------------------------------|---------|---------|--------|-------|------------|---------------------|--------------------------------------------------------------------|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | M-H, Random, 95% CI |
| Coviello 2010 | 3 | 31 | 1 | 32 | 100.0% | 3.10 [0.34, 28.19] | |
| Total (95% CI) | | 31 | | 32 | 100.0% | 3.10 [0.34, 28.19] | |
| Total events | 3 | | 1 | | | | |
| Heterogeneity: Not ap Test for overall effect | • • | | | | | | 0.01 0.1 1 1 10 100 Favours naîtrex. + psych. Favours psychosocial |

Figure 114: Days of criminal activity per month (6 month follow-up)






Figure 115: Adverse events (12-month follow-up)



0.4.2.3 Methadone versus waitlist control

Figure 116: Drop-out at post-treatment






Figure 118: Re-incarceration at 4-year follow-up

| | | | | | . , | | | | | | |
|---------------------------------------|------------------|----------------------------|---------------|-------------------|-----------------------|---------------------|------|---------------------------------------------|--|--|--|
| _ | methad | methadone waitlist control | | | _ | Risk Ratio | | Risk Ratio | | | |
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | | M-H, Random, 95% CI | | | |
| 28.3.1 1-month follow | w-up | | | | | | | | | | |
| Rich 2015 Subtotal (95% CI) | 12 | 109 109 | 8 | 87 87 | 2.0% 2.0% | | | - | | | |
| Total events Heterogeneity: Not ap | 12 pplicable | | 8 | | | | | | | | |
| Test for overall effect | Z = 0.42 (| P = 0.6 | 8) | | | | | | | | |
| 28.3.2 4-year follow- | up | | | | | | | | | | |
| Dolan 2005 Subtotal (95% CI) | 143 | 191 191 | 137 | 191 191 | 98.0% 98.0% | | | • | | | |
| Total events Heterogeneity: Not ap | 143 oplicable | | 137 | | | | | | | | |
| Test for overall effect | Z = 0.69 (| P = 0.4 | 9) | | | | | | | | |
| Total (95% CI) | | 300 | | 278 | 100.0% | 1.05 [0.93, 1.18] | | • | | | |
| Total events | 155 | | 145 | | | | | | | | |
| Heterogeneity: Tau² = | = 0.00; Chi | z = 0.11 | , df = 1 (P = | 0.74); P | ² =0% | | 0.01 | 0.1 1 10 100 | | | |
| Test for overall effect: | Z = 0.75 (| P = 0.4 | 6) | | | | 0.01 | Favours methadone Favours waitlist control | | | |
| Test for subgroup dif | ferences: (| Chi ^z = 0 | 0.10, df = 1 | P = 0.75 | 5), $I^2 = 0\%$ | 1 | | r avours methadone i avours waldist control | | | |

Figure 119: Adverse events (1-month follow-up)




Figure 120: Number of participants in contact with MH/substance misuse services (1-month follow-up)





Figure 121: Any drug use (1-month follow-up)



O.4.2.4 Alpha-adrenergic agonists versus opioid maintenance

Figure 122: Total withdrawal symptoms at post-treatment





0.4.2.5 Opioid substitution versus active intervention

Figure 123: Drop-out at post-treatment


| | buprenorphine other active interventi | | | ion | | Risk Ratio | | Ratio | | |
|-----------------------------------|---------------------------------------|---------|----------------------------------------|-------|--------|---------------------|------|-----------------------|---------------------------|-----|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | | M-H, Rand | om, 95% CI | |
| Magura 2009 | 11 | 60 | 14 | 56 | 48.8% | 0.73 [0.36, 1.48] | | _ | _ | |
| Sheard 2009 | 10 | 42 | 15 | 48 | 51.2% | 0.76 [0.38, 1.51] | | - | | |
| Total (95% CI) | | 102 | | 104 | 100.0% | 0.75 [0.46, 1.22] | | • | - | |
| Total events | 21 | | 29 | | | | | | | |
| Heterogeneity: Tau ² = | = 0.00; Chi ² = | 0.01, d | if = 1 (P = 0.94); I ² = 0% | | | | 0.01 | 01 | 10 | 100 |
| Test for overall effect: | Z=1.16 (P | = 0.24) | | | | | 0.01 | Favours buprenorphine | Favours other active int. | 100 |

Figure 124: Abstinence at post-treatment









Test for subgroup differences: $Chi^2 = 0.00$, df = 1 (P = 0.97), $I^2 = 0\%$

Figure 127: Number of times re-arrested (3 month follow-up)





Figure 128: Re-arrest for drug crimes (3 month follow-up)





| | buprenorphine methad | | | | | Risk Ratio | Risk Ratio | | | |
|--------------------------|----------------------|---------|--------|-------|--------|--------------------|-----------------------------------------|--|--|--|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI | | | |
| Magura 2009 | 24 | 60 | 28 | 56 | 100.0% | 0.80 [0.53, 1.20] | - | | | |
| Total (95% CI) | | 60 | | 56 | 100.0% | 0.80 [0.53, 1.20] | • | | | |
| Total events | 24 | | 28 | | | | | | | |
| Heterogeneity: Not ap | | | | | | | 0.01 0.1 1 10 100 | | | |
| Test for overall effect: | Z = 1.08 (P | = 0.28) | | | | | Favours buprenorphine Favours methadone | | | |

0.4.3 Combined psychological and pharmacological interventions

O.4.3.1 Antidepressants plus psychological therapy versus psychological therapy alone for substance misuse

Figure 130: Number of participants who failed to complete treatment at posttreatment




Figure 131: Spielberger State Anxiety Inventory score at post-treatment






Figure 132: Hamilton Depression Rating Scale score at post-treatment



O.4.4 Support and educational interventions

O.4.4.1 Psychoeducation versus control or treatment as usual

Figure 133: Number of days with uncontrolled drinking at post-treatment



O.4.4.2 Employment workshop versus control or treatment as usual

Figure 134: Number of participants employed at post-treatment

| | Employment wor | kshop | Control | TAU | | Risk Ratio | Risk Ratio |
|-----------------------------------|-----------------------|-------|---------------------------|-------|--------|---------------------|-----------------------------------------------|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | I M-H, Random, 95% CI |
| Hall 1981 | 24 | 28 | 13 | 24 | 38.0% | 1.58 [1.06, 2.36] | i] — |
| Webster 2014 | 196 | 244 | 176 | 233 | 62.0% | 1.06 [0.97, 1.17] | 1 🟴 |
| Total (95% CI) | | 272 | | 257 | 100.0% | 1.24 [0.84, 1.81] | 1 |
| Total events | 220 | | 189 | | | | |
| Heterogeneity: Tau ² = | | | : 0.05); l ^z : | = 73% | | | 0.1 0.2 0.5 1 2 5 10 |
| Test for overall effect: | : Z = 1.09 (P = 0.28) | | | | | | Favours control/TAU Favours employment w-shop |

Figure 135: Days in paid employment at post-treatment

| | Employn | nent work | shop | Cor | ntro6/TA | U | | Mean Difference | | Mean | Difference | ifference | |
|-------------------|---------|-----------|-------|-------|----------|-------|--------|-----------------------|------|--------------------|-------------|-------------|---------|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | | IV, Ran | dom, 95% C | 1 | |
| Webster 2014 | 210.1 | 114.1 | 244 | 199.9 | 130.1 | 233 | | 10.20 [-11.80, 32.20] | | | 1 | e e e | 2000.04 |
| | | | | | | | | | -100 | -50 | 0 | 50 | 100 |
| | | | | | | | | | | Favours control/TA | III Enweure | employment: | w-shop |

O.4.5 Physical interventions

O.4.5.1 Acupuncture versus active intervention

Figure 136: Drop-out at post-treatment





Figure 137: Urine test positive for drug use at post-treatment



O.5 Interventions for 'other' mental health disorders


O.5.1 Depression

0.5.1.1 Psychotherapy vs PSYCHOED

Figure 138: Depression by HRSD scales (at post-treatment)

| IPT | | | | PSY | CHOE | D | | Mean Difference | Mean Difference |
|---------------------------------------------------|------|-----|-------|------|------|-------|--------|-----------------------|-------------------------------------------------|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Fixed, 95% CI | IV, Fixed, 95% CI |
| Johnson 2012 | 14.1 | 8.3 | 19 | 20.6 | 10.5 | 19 | 100.0% | -6.50 [-12.52, -0.48] | - |
| Total (95% CI) | | | 19 | | | 19 | 100.0% | -6.50 [-12.52, -0.48] | • |
| Heterogeneity: Not ap Test for overall effect: | | | 0.03) | | | | | | -20 -10 0 10 20 Favours IPT Favours PSYCHOED |

Figure 139: Depression by HRSD scales at 13-weeks follow-up



O.5.1.2 Group therapy vs Individual therapy

Figure 140: Depression by BDI scales at post-treatment




Figure 141: Depression by Hopeless scale at post-treatment




Figure 142: Depression by MMPI D scale at post-treatment

| | | | | | Individual therapy Mean Difference | | | | | Mean Difference | | | |
|---------------------------------------------------|------|-------|-------|------|------------------------------------|-------|--------|----------------------|------|------------------------------|------------------|----------------------|-----|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Fixed, 95% CI | | IV, Fixe | d, 95% CI | | |
| Wilson 1990 | 69.8 | 14.56 | 5 | 57.2 | 10.98 | 5 | 100.0% | 12.60 [-3.38, 28.58] | | - | | | |
| Total (95% CI) | | | 5 | | | 5 | 100.0% | 12.60 [-3.38, 28.58] | | | • | | |
| Heterogeneity: Not ap Test for overall effect: | | | 12) | | | | | | -100 | -50 Favours group therapy | 0 Favours inc | 50 dividual thera | 100 |

Figure 143: Depression by MMPI D scale at 39-weeks follow-up





Figure 144: Depression by Multiple affect adjective checklist D scale at posttreatment



O.5.1.3 Arts-based Therapy vs TAU

Figure 145: Change in Adult Nowicki-Strickland Locus of Control Scale (ANS) at post-treatment




Figure 146: Change in Beck Depression Inventory (BDI): Total at post-treatment





Figure 147: Change in formal elements of arts therapy scale rating guide (FEATS):

Prominence of colour at post-treatment

| | Arts Therapy | | | | TAU | | | Mean Difference | Mean Difference | | |
|-------------------------------------------------------------------------------|--------------|-----|-------|------|------|-------|--------|----------------------|----------------------------------------------|--|--|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Fixed, 95% CI | IV, Fixed, 95% CI | | |
| Gussak 2009 | -0.39 | 1.1 | 65 | 0.42 | 1.44 | 19 | 100.0% | -0.81 [-1.51, -0.11] | | | |
| Total (95% CI) | | | 65 | | | 19 | 100.0% | -0.81 [-1.51, -0.11] | | | |
| Heterogeneity: Not applicable Test for overall effect: Z = 2.27 (P = 0.02) | | | | | | | | | -4 -2 0 2 4 Favours TAU Favours Arts Therapy | | |

Figure 148: Change in formal elements of arts therapy scale rating guide (FEATS):

Colour Fit at post-treatment



O.5.2 Vulnerable inmates with suicidal risks

O.5.2.1 Social problem solving group vs No treatment control

Figure 149: Depression by HADS scales at post-treatment




Figure 150: Anxiety by HADS scales at post-treatment




Figure 151: Depression by Beck Hopeless scales at post-treatment

| | Group therapy | | | No treati | nent cor | ntrol | | Mean Difference | Mean Difference | | | |
|---------------------------------------------------|---------------|--------|-------|-----------|----------|-------|--------|----------------------|-----------------|------------------------------|--------------------------|-----|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Fixed, 95% CI | | IV, Fixe | d, 95% CI | |
| Biggam 2002 | 3.9 | 3.5 | 23 | 6.4 | 4.7 | 23 | 100.0% | -2.50 [-4.89, -0.11] | | | | |
| Total (95% CI) | | | 23 | | | 23 | 100.0% | -2.50 [-4.89, -0.11] | | | | |
| Heterogeneity: Not ap Test for overall effect: | | (P = 0 | 1.04) | | | | | | -100 | -50 Favours group therapy | 0 50 Favours no treat | 100 |

Figure 152: Decision making ability by SPSI:R scales at post-treatment

| | Group therapy | | | No treatr | nent co | ntrol | Mean Difference | | | Mean Difference | | | |
|-------------------------------------------------|---------------|-----|--------|-----------|---------|-------|-----------------|-------------------|------|----------------------------|--------------|---------------------|-----|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Fixed, 95% CI | | IV, Fixe | d, 95% CI | | |
| Biggam 2002 | 12.1 | 4.2 | 23 | 6.8 | 4.9 | 23 | 100.0% | 5.30 [2.66, 7.94] | | | | | |
| Total (95% CI) | | | 23 | | | 23 | 100.0% | 5.30 [2.66, 7.94] | | | ♦ | | |
| Heterogeneity: Not a Test for overall effect | | | .0001) | | | | | | -100 | -50 Favours no treatmen | 0 Favours | 50 group therapy | 100 |

Figure 153: Depression by HADS scales at 13-weeks follow-up




Figure 154: Anxiety by HADS scales at 13-weeks follow-up




Figure 155: Depression by Beck Hopeless scales (13 weeks follow-up)

| | Group | thera | ру | No treatr | nent cor | ntrol | | Mean Difference | Mean Difference |
|---------------------------------------------------------------------|-------|--------|-------|-----------|----------|-------|--------|----------------------|--------------------------------------------------------------|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Fixed, 95% CI | IV, Fixed, 95% CI |
| Biggam 2002 | 4.2 | 2.9 | 23 | 7 | 4.9 | 23 | 100.0% | -2.80 [-5.13, -0.47] | • |
| Total (95% CI) Heterogeneity: Not ap Test for overall effect: | | (P = 0 | .02) | | | 23 | 100.0% | -2.80 [-5.13, -0.47] | -100 -50 0 50 100 Favours group therapy Favours no treatment |

O.5.3 Anxiety disorder

O.5.3.1 Self-help therapy vs Wait-list control

Figure 156: Anxiety by HADS scales at post-treatment





Figure 157: Anxiety by HADS scales at 4-weeks follow-up

| | Self-hel | Self-help therapy Wait-list control | | | | trol | | Mean Difference | Mean Difference | | | | |
|---------------------------------------------------|----------|-------------------------------------|-------|-------|------|-------|--------|----------------------|-----------------|------------------------------|--------------|--------------------------------|-----|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Fixed, 95% CI | | IV, | Fixed, 9 | 5% CI | |
| Maunder 2009 | 10.89 | 4.1 | 15 | 13.87 | 4.19 | 18 | 100.0% | -2.98 [-5.82, -0.14] | | | | | |
| Total (95% CI) | | | 15 | | | 18 | 100.0% | -2.98 [-5.82, -0.14] | | | • | | |
| Heterogeneity: Not ap Test for overall effect: | • | P = 0.0 | 4) | | | | | | -100 | -50 Favours self-help the | 0 rapy Fa | 50 avours wait-list control | 100 |

0.5.4 PTSD

0.5.4.1 Psychotherapy vs Control

Figure 158: Trauma by TSI at post-treatment



0.5.4.2 TIR vs Wait-list control

Figure 159: Depression by BDI scales at post-treatment




Figure 160: Depression by BDI scales at 13 weeks follow-up




Figure 161: PTSD by PSS scales at post-treatment




Figure 162: PTSD by PSS scales (13 weeks follow-up)

| | | TIR Control Mean SD Total Mean SD Total | | | | | | Mean Difference | | Mean Difference | | | | |
|---------------------------------------------------|------|-----------------------------------------|--------|------|------|-------|--------|-----------------------|------|-----------------|------------------|---------------------|----------------|--|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Fixed, 95% CI | | IV | , Fixed, 95% | CI | | |
| Valentine 2001 | 8.5 | 9.7 | 56 | 15.8 | 13.9 | 67 | 100.0% | -7.30 [-11.49, -3.11] | | | | | | |
| Total (95% CI) | | | 56 | | | 67 | 100.0% | -7.30 [-11.49, -3.11] | | | • | | | |
| Heterogeneity: Not ap Test for overall effect: | | | 0.0006 | 6) | | | | | -100 | -50 Favou | 0 rs TIR Favo | 50 urs wait-list | 100 control | |

Figure 163: Generalized Expectancy by Success scale at post-treatment

| | | | | | ist con | trol | | Mean Difference | Mean Difference |
|---------------------------------------------------|------|------|--------|-------|---------|-------|--------|---------------------|---------------------------------------------------------|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Fixed, 95% CI | IV, Fixed, 95% CI |
| Valentine 2001 | 122 | 33.8 | 56 | 106.1 | 21.2 | 67 | 100.0% | 15.90 [5.70, 26.10] | - |
| Total (95% CI) | | | 56 | | | 67 | 100.0% | 15.90 [5.70, 26.10] | • |
| Heterogeneity: Not ap Test for overall effect: | | | 0.002) | | | | | | -100 -50 0 50 100 Favours wait-list control Favours TIR |

Figure 164: Generalized Expectancy for Success scales at 13-weeks follow-up




Figure 165: Clinical anxiety scales at post-treatment





Figure 166: Clinical anxiety scales at 13-weeks follow-up at post-treatment



0.5.4.3 TARGET vs SGT

Figure 167: PTSD symptoms by CAPS scales at post-treatment




Figure 168: Heartland forgiveness scales at post-treatment

| | TA | TARGET | | | SGT | | Mean Difference | | | Mean Difference | | | |
|---------------------------------------------------|------|--------|-------|------|------|-------|-----------------|---------------------|------|------------------|---------------|-----------------|----------|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Fixed, 95% CI | | IV, F | ixed, 95% (| CI . | |
| Ford 2013 | 81.3 | 11.8 | 23 | 76.7 | 15.7 | 9 | 100.0% | 4.60 [-6.73, 15.93] | | | - | | |
| Total (95% CI) | | | 23 | | | 9 | 100.0% | 4.60 [-6.73, 15.93] | | | • | | |
| Heterogeneity: Not ap Test for overall effect: | | | 0.43) | | | | | | -100 | -50 Favours S | 0 GT Favou | 50 rs TARGE1 | 100 T |

O.5.4.4 Focused group therapy vs Wait-list control

Figure 169: Symptom checklist-90 R: Global Severity Index at post-treatment




Figure 170: Symptom Checklist-90 R: Positive symptom distress index at posttreatment






Figure 171: Symptom Checklist-90 R: Positive Symptom Total at post-treatment



O.5.4.5 Group Therapy vs No contact control


Figure 172: IIP-32 scales at post-treatment



O.5.5 ADHD

0.5.5.1 MPH vs Placebo

Figure 173: Conner Adult ADHD rating scale - Observer:Screening Version (CAARS-OSV) at post-treatment (52 weeks)



Test for subgroup differences: Not applicable

Figure 174: Conner Adult ADHD rating scale - Observer:Screening version (CAARS-OSV) at 3-years follow-up





Figure 175: Number of participants with drug negative urine at post-treatment



O.5.6 Antisocial personality disorders

O.5.6.1 Tiagabine vs Placebo

Figure 176: Aggressive response at post-treatment




Figure 177: Number of subjects with adverse effects at post-treatment



O.5.7 Severe Mental Illness

0.5.7.1 IM Paliperidone vs Oral Antipsychotics for schizophrenia

Figure 178: First-time treatment failure at post-treatment

| | IM Paliperi | IM Paliperidone Oral antipsychotics | | | | Risk Ratio | Risk Ratio | | | |
|-------------------------------------------------|-------------|-------------------------------------|--------|-------|--------|---------------------|-------------------------------------------------------------------|----|--|--|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | M-H, Random, 95% CI | | | |
| Alphs 2015a | 90 | 226 | 117 | 218 | 100.0% | 0.74 [0.61, 0.91] | | | | |
| Total (95% CI) | | 226 | | 218 | 100.0% | 0.74 [0.61, 0.91] | ◆ | | | |
| Total events | 90 | | 117 | | | | | | | |
| Heterogeneity: Not a Test for overall effect | | = 0.004) | | | | | 0.01 0.1 1 10 1 Favours IM Paliperidone Favours Oral Antipsych | 00 | | |

Figure 179: Incidence of prolactin-related side-effects at post-treatment



O.5.7.2 The Citizenship Project vs TAU

Figure 180: Change in overall quality of life at post-treatment




Figure 181: Change in number of all convictions at post-treatment




Figure 182: Change in alcohol composite ratio at post-treatment

| | Citizen | | | | Citizenship Project | | | TAU | | | Mean Difference | Mean Difference |
|---------------------------------------------------|---------|-----------|-------|------|---------------------|-------|--------|----------------------|------------------------------------------------------|--|-----------------|-----------------|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Fixed, 95% CI | IV, Fixed, 95% CI | | | |
| Clayton 2013 | 0 | 0.732 | 73 | 0.29 | 0.732 | 41 | 100.0% | -0.29 [-0.57, -0.01] | - | | | |
| Total (95% CI) | | | 73 | | | 41 | 100.0% | -0.29 [-0.57, -0.01] | • | | | |
| Heterogeneity: Not ap Test for overall effect: | | (P = 0.04 |) | | | | | | -1 -0.5 0 0.5 1 Favours Citizenship proj Favours TAU | | | |

Figure 183: Change in brief psychiatric rating scale: withdrawal symptoms at posttreatment

| | Citize | nship Pro | ject | | TAU | | | Mean Difference | Mean Difference |
|-----------------------------------------------------|--------|-----------|-------|------|--------|-------|--------|-------------------|------------------------------------------------------|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Fixed, 95% CI | IV, Fixed, 95% CI |
| Clayton 2013 | 0.28 | 0.7059 | 73 | 0 | 0.7059 | 41 | 100.0% | 0.28 [0.01, 0.55] | _ |
| Total (95% CI) | | | 73 | | | 41 | 100.0% | 0.28 [0.01, 0.55] | • |
| Heterogeneity: Not ap Test for overall effect: 2 | • | |) | | | | | | -1 -0.5 0 0.5 1 Favours Citizenship Proj Favours TAU |

Figure 184: Change in addiction severity index: drug index at post-treatment

| | Citizenship Project | | | | | | | Mean Difference | Mean Difference | | |
|---------------------------------------------------|---------------------|--------|-------|------|--------|-------|--------|---------------------|----------------------------------------------------------|--|--|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Fixed, 95% CI | IV, Fixed, 95% CI | | |
| Clayton 2013 | 0 | 0.1046 | 73 | 0.04 | 0.1046 | 41 | 100.0% | -0.04 [-0.08, 0.00] | - | | |
| Total (95% CI) | | | 73 | | | 41 | 100.0% | -0.04 [-0.08, 0.00] | • | | |
| Heterogeneity: Not ap Test for overall effect: | | |) | | | | | | -0.2 -0.1 0 0.1 0.2 Favours Citizenship Proj Favours TAU | | |

0.5.7.3 IPS vs Peer Support

Figure 185: Competitive job placement




Figure 186: Number of hospitalizations





Figure 187: Number of days being hospitalized



O.5.8 Uncategorized mental health disorders

0.5.8.1 Parenting from inside (PFI) vs TAU

Figure 188: Parenting Stress Index at post-treatment

| | | PFI | | | TAU | | | Mean Difference | Mean Difference |
|------------------------------------------------|------|------|-------|------|------|-------|--------|--------------------|--------------------------------------------------|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI |
| Loper 2011 | 2.18 | 0.62 | 60 | 2.14 | 0.64 | 76 | 100.0% | 0.04 [-0.17, 0.25] | |
| Total (95% CI) | | | 60 | | | 76 | 100.0% | 0.04 [-0.17, 0.25] | |
| Heterogeneity: Not a Test for overall effec | | | 0.71) | | | | | | -0.5 -0.25 0 0.25 0.5 Favours PFI Favours TAU |

Figure 189: Parenting alliance at post-treatment





Figure 190: Brief Symptom Inventory (BSI): Total at post-treatment



O.5.8.2 Music therapy vs Standard care for mental health disorders

Figure 191: State and Trait Anxiety Inventory – State at post-treatment




Figure 192: State and Trait Anxiety Inventory – Trait at post-treatment




Figure 193: Brief Symptom inventory (BSI): Total at post-treatment

| Group Music Ther | | | ару | Stan | dard ca | are | Mean Difference | | | Mean Difference | | |
|-----------------------------------------------------|-------|-----------|-------|-------|---------|-------|-----------------|-----------------------|------|------------------------------|-------------------------------|-----|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Fixed, 95% CI | | IV, Fixed | 1, 95% CI | |
| Chen 2015 | 11.51 | 7.78 | 93 | 20.32 | 12.47 | 91 | 100.0% | -8.81 [-11.82, -5.80] | | | | |
| Total (95% CI) | | | 93 | | | 91 | 100.0% | -8.81 [-11.82, -5.80] | | • | | |
| Heterogeneity: Not ap Test for overall effect: : | | < 0.00001 |) | | | | | | -100 | -50 Favours music therapy | 0 50 Favours standard care | 100 |

Figure 194: Rosenberg self-esteem inventory at post-treatment

| | Group Music Therapy | | | Stand | lard c | аге | | Mean Difference | Mean Difference | | | |
|---------------------------------------------------|---------------------|----------|-------|-------|--------|-------|--------|-------------------|-----------------------------------------------------------|--|--|--|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Fixed, 95% CI | IV, Fixed, 95% CI | | | |
| Chen 2015 | 29.27 | 4.25 | 93 | 27.01 | 4.6 | 91 | 100.0% | 2.26 [0.98, 3.54] | | | | |
| Total (95% CI) | | | 93 | | | 91 | 100.0% | 2.26 [0.98, 3.54] | • | | | |
| Heterogeneity: Not ap Test for overall effect: | | = 0.0005 |) | | | | | | -10 -5 0 5 10 Favours standard care Favours music therapy | | | |

Figure 195: Texas social behaviour inventory at post-treatment



O.5.8.3 Music therapy vs Wait-list control for antisocial personality disorders

Figure 196: ASP-1: Change in self-management of psychiatric symptoms at posttreatment



Figure 197: ASP-4: Change in self-management of assaultive symptoms at post-treatment




Figure 198: ASP-9: Change in interpersonal skills at post-treatment




Figure 199: Change in social dysfunction and aggression scales at post-treatment




Figure 200: FP40: Change in positive coping skills at post-treatment

| | music | thera | ару | wait-list control | | | | Mean Difference | Mean Difference | | | | |
|---------------------------------------------------|-------|--------|-------|-------------------|------|-------|--------|-------------------|-----------------|---------------------------------|------------------|------------------|---|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Fixed, 95% CI | | IV, Fixe | d, 95% CI | | |
| Hakvoort 2013 | 0.45 | 0.4 | 8 | 0.02 | 0.15 | 5 | 100.0% | 0.43 [0.12, 0.74] | | | - | | |
| Total (95% CI) | | | 8 | | | 5 | 100.0% | 0.43 [0.12, 0.74] | | | • | | |
| Heterogeneity: Not ap Test for overall effect: | | (P = 0 | .006) | | | | | | -4 | -2 Favours wait-list control | 0 Favours mu: | 2 sic therapy | 4 |

O.6 Interventions for paraphilic disorders

O.6.1 MPA + psych intervention vs psych intervention only at post-treatment

Figure 201: Reduced anomalous desires




Figure 202: Repetition/persistence of anomalous behaviour





Figure 203: Drop out




O.6.2 MPA only vs psych intervention only at post-treatment

Figure 204: Reduced anomalous desires

| | Experimental | | Control | | | Risk Ratio | Risk Ratio | | | | |
|-------------------------|--------------|----------|---------------|-------|--------|---------------------|------------|---------------|--------------------------------------------------|--------|-----|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | | M-H, Ran | dom, 95% | CI | |
| McConaghy1988 | 3 | 10 | 6 | 10 | 100.0% | 0.50 [0.17, 1.46] | | | + | | |
| Total (95% CI) | | 10 | | 10 | 100.0% | 0.50 [0.17, 1.46] | | • | - | | |
| Total events | 3 | | 6 | | | | | | | | |
| Heterogeneity: Not a | oplicable | | | | | | 0.01 | 01 | | 10 | 100 |
| Test for overall effect | Z = 1.27 (F | o = 0.21 |) | | | | 0.01 | Favours psych | Favour | s drug | 100 |

Figure 205: Reduced anomalous behaviour



O.6.3 Psychoeducational interventions, principally CBT-informed psychoeducation (including SOTP) versus treatment as usual, no treatment or waitlist control for paraphilic disorders

Figure 206: Cognitive distortions (ABCS: Children and Sex Questionnaire)




Figure 207: Sexual obsessions (RCTs)




Figure 208: Reconviction (any): CJS database; controlled non-randomised studies; longest follow-up available 2-7 years




Figure 209: Sexual reconviction: CJS database; controlled non-randomised studies; longest follow-up available [2-11 years]




Figure 210: Violent reconviction: CJS database; controlled non-randomised studies; longest follow-up available [3-11 years]




Figure 211: Revocation, breaches of the Sex Offender Register or probation violation (CJS database; controlled non-randomised studies; longest follow-up available [2-5 years])

| | Experime | ental | Control | | | Risk Ratio | Risk Ratio | | | | |
|-------------------------------------|-------------|-----------------|---------------|-------------------|-----------------------|-----------------------------------------------|--------------------------|--------------------|------------------|-------------|----|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | M- | H, Randor | m, 95% CI | | |
| 1.32.1 UK | | | | | | | | | | | |
| Craissati 2009 Subtotal (95% CI) | 7 | 95 95 | 35 | 145 145 | 17.6% 17.6% | 0.31 [0.14, 0.66] 0.31 [0.14, 0.66] | | _ | | | |
| Total events | 7 | | 35 | | | | | | | | |
| Heterogeneity: Not ap | plicable | | | | | | | | | | |
| Test for overall effect: | Z = 3.02 (F | 9 = 0.00 | 2) | | | | | | | | |
| 1.32.2 US | | | | | | | | | | | |
| Lowden 2003 | 48 | 160 | 625 | 1310 | 23.1% | 0.63 [0.49, 0.80] | | - | | | |
| McGrath 1998 | 18 | 71 | 18 | 51 | 20.2% | 0.72 [0.42, 1.24] | | | _ | | |
| McGuire 2000 | 11 | 54 | 9 | 14 | 18.9% | 0.32 [0.16, 0.61] | | — | | | |
| Stalans 2001 | 20 | 78 | 22 | 208 | 20.2% | 2.42 [1.40, 4.19] | | | | - | |
| Subtotal (95% CI) | | 363 | | 1583 | 82.4% | 0.77 [0.39, 1.55] | | $\overline{}$ | - | | |
| Total events | 97 | | 674 | | | | | | | | |
| Heterogeneity: Tau ^z = | 0.44; Chi² | = 26.18 | 3, df = 3 (1) | P < 0.0 | 0001); l²= | : 89% | | | | | |
| Test for overall effect: | Z = 0.73 (F | r = 0.47 |) | | | | | | | | |
| Total (95% CI) | | 458 | | 1728 | 100.0% | 0.66 [0.35, 1.23] | - | | - | | |
| Total events | 104 | | 709 | | | | | | | | |
| Heterogeneity: Tau ² = | 0.43; Chi² | = 30.57 | ', df = 4 (l | P < 0.0 | 0001); l² = | : 87% | 10100 | | | | - |
| Test for overall effect: | Z = 1.32 (F | = 0.19 |) | | | 1 | 0.1 0.2 Favours exper | 0.5 1 imental l | Z Egyptire co | _ | 10 |
| Test for subgroup diff | erences: C | $hi^2 = 3$. | 08. df = 1 | (P = 0. | $.08$), $I^2 = 6$ | 7.5% | avours exper | intental I | ravours co | naoi | |

O.6.4 Reintegration programmes versus treatment as usual for paraphilic disorders

Figure 212: Reconviction at 2- to 4-year follow-up (CJS database)




Figure 213: Sex offence reconviction at 3- or 4-year follow-up (CJS database)

| | Experimental C | | Contr | ol | | Risk Ratio | Risk Ratio |
|-----------------------------------|----------------|----------|------------|---------|----------------|---------------------|--------------------------------------------------------------|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | M-H, Random, 95% CI |
| 3.5.1 UK | | | | | | | |
| Bates 2014 | 4 | 71 | 5 | 71 | 41.0% | 0.80 [0.22, 2.86] | <u> </u> |
| Subtotal (95% CI) | | 71 | | 71 | 41.0% | 0.80 [0.22, 2.86] | |
| Total events | 4 | | 5 | | | | |
| Heterogeneity: Not ap | plicable | | | | | | |
| Test for overall effect: | Z = 0.34 (P) | 9 = 0.73 |) | | | | |
| 3.5.2 Canada | | | | | | | |
| Wilson 2007 | 3 | 60 | 10 | 60 | 43.2% | 0.30 [0.09, 1.04] | ← |
| Wilson 2009 | 1 | 44 | 6 | 44 | 15.8% | 0.17 [0.02, 1.33] | |
| Subtotal (95% CI) | | 104 | | 104 | 59.0% | 0.26 [0.09, 0.75] | |
| Total events | 4 | | 16 | | | | |
| Heterogeneity: Tau² = | 0.00; Chi² | = 0.23, | df = 1 (P | = 0.63) |); I² = 0% | | |
| Test for overall effect: | Z = 2.50 (P | 9 = 0.01 |) | | | | |
| Total (95% CI) | | 175 | | 175 | 100.0% | 0.41 [0.18, 0.94] | - |
| Total events | 8 | | 21 | | | | |
| Heterogeneity: Tau ² = | 0.02; Chi² | = 2.06, | df = 2 (P | = 0.36) |); I² = 3% | | |
| Test for overall effect: | Z = 2.11 (P | r = 0.03 |) | | | | Ö.1 0.2 0.5 1 2 5 10 Favours experimental Favours control |
| Test for subgroup diffe | erences: C | hi² = 1. | 80, df = 1 | (P = 0. | 18), $I^2 = 4$ | 4.4% | ravouis experimental Favouis Control |

Figure 214: Violent reconviction at 3 to 4 years follow-up (CJS database)





Figure 215: Reincarceration for a technical violation revocation or failure to comply with Sex Offender's Register (SOR) requirements at 2- or 4-year follow-up (CJS database)



O.6.5 Imaginal desensitization plus MPA versus MPA for paraphilic disorders

Figure 216: Anomalous desire





Figure 217: Adverse events



O.6.6 Imaginal desensitization versus covert sensitization for paraphilic disorders

Figure 218: Anomalous desire





Figure 219: Loss to follow up



O.7 Service delivery models

O.7.1 Street Triage (Before versus After)

Figure 220: Total s136 detentions per 100,000




Figure 221: Number of s136 detentions in custody



Figure 222: Number of s136 detentions in hospital

| | After ST scheme | | Before ST s | scheme | | Risk Ratio | Risk Ratio |
|--------------------------|------------------|------------|-------------|--------|--------|--------------------|------------------------------------------------------------|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI |
| Hywel Dda 2015 | 141 | 198 | 127 | 227 | 0.7% | 1.27 [1.10, 1.47] | |
| Pilling 2016 | 18461 | 24489 | 16000 | 25000 | 99.2% | 1.18 [1.16, 1.19] | |
| Powys 2015 | 11 | 16 | 12 | 23 | 0.1% | 1.32 [0.79, 2.20] | |
| Total (95% CI) | | 24703 | | 25250 | 100.0% | 1.18 [1.16, 1.19] | • |
| Total events | 18613 | | 16139 | | | | |
| Heterogeneity: Chi²= | 1.27, $df = 2$ (| (P = 0.53) | ; I² = 0% | | | - | 0.7 0.85 1 1.2 1.5 |
| Test for overall effect: | Z = 27.56 (P | < 0.0000 | 01) | | | | U.7 U.85 1 1.2 1.5 Favours no ST scheme Favours ST scheme |

0.7.2 Diversion Services

0.7.2.1 Before and After Diversion Services

Figure 223: Duration between remand assessment (days)





Figure 224: Days of total time on remand



0.7.2.2 Assessment versus No assessment at court

Figure 214: Proportions of prisoners on bail




Figure 215: Attendance at alcohol and drug treatment programmes





Figure 216: OPD attendance rates for those release on bail

| | Assessment Control | | | Risk Ratio | Risk Ratio | | |
|---------------------------------------------------|--------------------|----------|--------|------------|------------|--------------------|------------------------------------------------------|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI |
| Chambers 1999 | 11 | 23 | 7 | 13 | 100.0% | 0.89 [0.46, 1.72] | - |
| Total (95% CI) | | 23 | | 13 | 100.0% | 0.89 [0.46, 1.72] | • |
| Total events | 11 | | 7 | | | | |
| Heterogeneity: Not ap Test for overall effect: | | P = 0.72 |) | | | | 0.01 0.1 1 10 100 Favours Assessment Favours Control |

Figure 217: Registration of care programmes (CPA) and supervision registration (SR)



0.7.2.3 Court Diversion vs Community Diversion

Figure 225: Rate of re-incarceration in two years after index discharge



Figure 226: 100% attendance rate of appointments




Figure 227: Number of days in hospital




Figure 228: Number of diverted participants with no mental health disorders

| | Court Diversion | | Community Div | version | | Risk Ratio | | Risk Ratio | | |
|---------------------------------------------------|-----------------|---------|---------------|---------|--------|----------------------|-------|----------------------|-------------------|---------------|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Fixed, 95% CI | | M-H, Fixe | d, 95% CI | |
| James 2002 | 6 | 214 | 0 | 214 | 100.0% | 13.00 [0.74, 229.33] | | - | | |
| Total (95% CI) | | 214 | | 214 | 100.0% | 13.00 [0.74, 229.33] | | - | | _ |
| Total events | 6 | | 0 | | | | | | | |
| Heterogeneity: Not ap Test for overall effect: | | = 0.08) | | | | | 0.002 | 0.1 Favours court | 10 Favours com | 500 munity |

O.7.3 Patient Navigation Intervention versus facilitated enrolment (at 26-weeks follow-up)


Figure 229: Number of participants who used drugs



Figure 230: Number of participants who used alcohol to intoxication



Figure 231: Average days when mental health was not good in the last 30 days



O.7.4 Neighbourhood outreach (Before versus After)

Figure 232: Proportion of crime contacts with policing team escalated to court



O.7.5 Drug Rehabilitation Program versus TAU

Figure 233: MAP total scores




Figure 234: HoNOS total scores





Figure 235: Overall satisfaction



O.7.6 Case management

0.7.6.1 Case management vs TAU for substance misuse disorders

Figure 236: Re-arrest at post-treatment and 3-months follow-up




Figure 237: Reconviction at post-treatment





Figure 238: Re-incarceration

At post-treatment and 3-months follow-up



ii) At 12-months follow-up




Figure 239: Number of days jailed in past 6 months (12-months follow-up)





Figure 240: Drug related crimes in past 6 months (12-months follow-up)




Drug related crime activity during treatment (12-months follow-up) Figure 241:



Figure 242: Self-reported alcohol use

i) During treatment and post-treatment



Test for subgroup differences: $Chi^2 = 3.25$, df = 1 (P = 0.07), $I^2 = 69.2\%$

ii) 12-months follow-up





Figure 243: Self-reported drug use

i) During treatment (marijuana or hard drugs) or post-treatment



ii) 12-months follow-up

case management TAU Risk Ratio Study or Subgroup **Events** Total Events Total Weight M-H, Random, 95% CI M-H, Random, 95% CI 18.14.4 12 month follow-up: female sample Johnson 2011 8 77 13 0.62 [0.27, 1.40] Subtotal (95% CI) 0.62 [0.27, 1.40] 77 9.5% Total events 13 Heterogeneity: Not applicable Test for overall effect: Z = 1.16 (P = 0.25) 18.14.5 12 month follow-up: male sample 354 Johnson 2011 74 95 90.5% 0.78 [0.60, 1.02] Subtotal (95% CI) 354 354 90.5% 0.78 [0.60, 1.02] 95 Total events Heterogeneity: Not applicable Test for overall effect: Z = 1.84 (P = 0.07) Total (95% CI) 431 100.0% 0.76 [0.59, 0.98] 431 Total events 82 108 Heterogeneity: $Tau^2 = 0.00$; $Chi^2 = 0.29$, df = 1 (P = 0.59); $I^2 = 0\%$ 0.01 100 0.1 10 Test for overall effect: Z = 2.11 (P = 0.03)

Favours case management Favours TAU

Figure 244: Injection drug use (post-treatment)

Test for subgroup differences: $Chi^2 = 0.29$, df = 1 (P = 0.59), $I^2 = 0\%$





Figure 245: Abstinence



0.7.6.2 Case management vs active intervention for substance misuse disorders

Figure 246: Remained in treatment for 6 months




Figure 247: Re-arrest at post-treatment and 3-months follow-up




Figure 248: Rearrest for drug crime (3 months follow-up)




Figure 249: Reconviction at post-treatment and 3-months follow-up




Figure 250: Re-incarceration at post-treatment and 3-months follow-up




Figure 251: Any self-reported drug use (3-months follow-up)





Figure 252: Positive hair test (3-months follow-up)



Test for subgroup differences. Crim= 2.81, di = 1 (P = 0.09), IP= 64.49

0.7.6.3 Assertive Community Treatment vs TAU for substance misuse disorders

Figure 253: Urine test positive for drug use during treatment



Figure 254: Self-reported injection drug use during treatment



Figure 255: Self-reported drug use during treatment



Figure 256: Re-incarceration during treatment



0.7.6.4 Case management vs TAU for mental health disorders other than substance misuse

Figure 257: Service utilization at post-treatment

| | Case manage | ment | TAU | J | | Risk Ratio | | Risk Ratio | |
|--------------------------|--------------------|-----------|------------|------------------|--------|---------------------|------|-----------------------------------|---|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | | M-H, Random, 95% CI | |
| Jarret 2012 | 11 | 15 | 4 | 8 | 33.4% | 1.47 [0.69, 3.13] | | | |
| Wang 2012 | 37 | 98 | 48 | 102 | 66.6% | 0.80 [0.58, 1.11] | | - | |
| Total (95% CI) | | 113 | | 110 | 100.0% | 0.98 [0.56, 1.72] | | • | |
| Total events | 48 | | 52 | | | | | | |
| Heterogeneity: Tau² = | : 0.09; Chi² = 2.0 | 7, df = 1 | (P = 0.19) | 5); P = 6 | 52% | | 0.01 | 0.1 1 10 10 | 7 |
| Test for overall effect: | Z = 0.07 (P = 0.9) | 35) | | | | | 0.01 | Favours TAU Favours Case manageme | |

Figure 258: Rate of re-offending at post-treatment




Figure 259: Number of days in jail (up to 24-months follow-up)





Figure 260: Quality of Life at post-treatment



O.7.7 Drug court

0.7.7.1 Drug court vs TAU

Figure 261: Days of substance misuse (12 months follow-up)





Figure 262: Re-arrest (12-month follow-up)



Figure 263: Maximum Crime Seriousness Scale (12-months follow-up)



0.7.7.2 Drug court vs active intervention

At post-treatment

Figure 264: Removed from treatment due to unsatisfactory progress



Figure 265: Addiction Severity Index (ASI): alcohol composite scores




Figure 266: Addiction severity index (ASI): drug composite score




Figure 267: Number of sanctions during treatment




Figure 268: Number of sanctions during treatment resulting in jail detention




Figure 269: Reincarceration during treatment





Figure 270: Urine test positive for drugs (post-treatment)



0.7.8 Opioid substitution therapy

0.7.8.1 Opioid substitution therapy + case management vs active intervention

Figure 271: Completed jail treatment




Figure 272: Urine test positive for cocaine




Figure 273: Urine test positive for opioids




Figure 274: Days of substance use (12-months follow-up)




Figure 275: Self-reported drug use in past 30 days (6-months follow-up)




Figure 276: Drug overdose at 6-months and 12-months follow-up




Figure 277: Re-arrest at 6-months and 12-months follow-up





Figure 278: Self-reported days of criminal activity (12 months follow-up)



O.7.9 Automated Telephony (AT) with feedback versus AT alone

Figure 279: Change in Arnetz and Hasson stress questionnaires (AHSS)




Figure 280: Change in symptom checklist-8D (SCL-8D)

| | AT wi | | | | T alone | | | Mean Difference | Mean Difference | | |
|---------------------------------------------------|-------|-------|-------|------|---------|-------|--------|-------------------|-----------------------------------------------------------|--|--|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Fixed, 95% CI | IV, Fixed, 95% CI | | |
| Andersson 2014 | 3.3 | 10.96 | 52 | -1.2 | 11.76 | 56 | 100.0% | 4.50 [0.22, 8.78] | - | | |
| Total (95% CI) | | | 52 | | | 56 | 100.0% | 4.50 [0.22, 8.78] | ◆ | | |
| Heterogeneity: Not ap Test for overall effect: | | | 04) | | | | | | -20 -10 0 10 20 Favours AT alone Favours AT with feedback | | |

Figure 281: Change in daily stressor assessment




Figure 282: Alcohol urge questionnaires: reduction in alcohol urge




Figure 283: Alcohol urge questionnaires: reduction in alcohol use




Figure 284: Alcohol urge questionnaires: reduction in drug urge





Figure 285: Alcohol urge questionnaires: reduction in drug use



O.7.10 IDDT versus TAU


Figure 286: Number of days in hospital

| | ı | IDDT | | | TAU | | | Mean Difference | | Mea | n Differen | ce | |
|---------------------------------------------------|------|------|--------|-------|-------|-------|--------|----------------------|------|-------------------|---------------|---------------|-----|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Fixed, 95% CI | | IV, F | ixed, 95% | CI | |
| Chandler 2006 | 6.89 | 7.01 | 103 | 12.52 | 16.88 | 79 | 100.0% | -5.63 [-9.59, -1.67] | | | | | |
| Total (95% CI) | | | 103 | | | 79 | 100.0% | -5.63 [-9.59, -1.67] | | | • | | |
| Heterogeneity: Not ap Test for overall effect: | | | 0.005) | | | | | | -100 | -50 Favours ID | 0 DT Favor | 50 urs TAU | 100 |

Figure 287: Rate of crisis visits




Figure 288: Rate of outpatient medication services



O.7.11 Housing First versus TAU

Figure 289: Any offence




O.7.12 TIMA versus TAU

Figure 290: Bipolar Disorder Symptom Scale (BDSS)

| | TIMA | | | TAU | | | | Mean Difference | Mean Difference | | | | |
|-------------------------------------------------|------|------|-------|------|------|-------|--------|---------------------|-----------------|---------------|---------------------|--------------|---|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Fixed, 95% CI | | IV, | Fixed, 95% | CI | |
| Ehret 2013 | 1.22 | 1.02 | 30 | 1.49 | 0.89 | 30 | 100.0% | -0.27 [-0.75, 0.21] | | | - | | |
| Total (95% CI) | | | 30 | | | 30 | 100.0% | -0.27 [-0.75, 0.21] | | | • | | |
| Heterogeneity: Not a Test for overall effect | | | 0.27) | | | | | | -4 | -2 Favours | υ Ο ΓΙΜΑ Favo | 2 urs TAU | 4 |

Figure 291: Brief Psychiatric Rating Scale (BPRS)



O.7.13 Service Brokerage Intervention versus TAU

Figure 292: Number of participants in contact with MH services




Figure 293: Number of participants who have seen GP






Figure 294: Number of participants who attended alcohol or drug service



O.7.14 Therapeutic communities

0.7.14.1 Therapeutic community versus waitlist control

Figure 295: Days until re-incarceration



0.7.14.2 Therapeutic community versus active intervention

Figure 296: Addiction Severity Index (ASI-6): alcohol composite score




Figure 297: Addiction Severity Index (ASI-6): drug composite score



Figure 298: Alcohol use at follow-up




Figure 299: Frequency of alcohol use at follow-up




Figure 300: Frequency of drug use at follow-up





Figure 301: Drug use at follow-up









Figure 303: Re-incarceration at follow-up









0.7.14.3 Modified therapeutic community versus psychoeducation

Figure 306: Substance use (12 month follow-up)




Figure 307: Alcohol use (12 month follow-up)





Figure 308: Drug use (12 month follow-up)





| | Modifie | d TC. | CBT psyc | hoed. | | Risk Ratio | | Risk F | Ratio | |
|------------------------------------------------|---------|----------|----------|-------|--------|---------------------|------|---------------------------|--------------------------|-----|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | | M-H, Rando | m, 95% CI | |
| Sacks 2004 | 35 | 75 | 45 | 64 | 100.0% | 0.66 [0.50, 0.89] | | - | | |
| Total (95% CI) | | 75 | | 64 | 100.0% | 0.66 [0.50, 0.89] | | • | | |
| Total events | 35 | | 45 | | | | | | | |
| Heterogeneity: Not a Test for overall effec | | P = 0.01 | 06) | | | | 0.01 | 0.1 1 Favours modified TC | 10 Favours CBT psychoed. | 100 |

Figure 310: Re-incarceration (12 month follow-up)





Figure 311: Alcohol or drug offences (12 month follow-up)



0.7.14.4 Enhanced therapeutic community versus standard therapeutic community

At post-treatment

Figure 312: Engagement with treatment




Figure 313: Negative mood (rated by counsellors)

| | enhanced TC standard TC | | | | TC | | Mean Difference | Mean Difference | | | | | | | |
|-------------------------------------------------|-------------------------|------|--------|------|-----|-------|-----------------|----------------------|----|-----------------|----------------|--------------|------------|--------|---|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | | | IV, Rando | m, 95% (| 1 | | |
| Czuchry 2003 | 2.67 | 1.37 | 230 | 4.46 | 1.8 | 219 | 100.0% | -1.79 [-2.09, -1.49] | | | | | | | |
| Total (95% CI) | | | 230 | | | 219 | 100.0% | -1.79 [-2.09, -1.49] | | | • | | | | |
| Heterogeneity: Not a Test for overall effect | | | 0.0000 | 01) | | | | | -4 | - Favours en | 2 hanced TC | 0 Eavours | 2 stand | ard TC | 4 |

0.7.14.5 Gender-responsive therapeutic community versus standard therapeutic community

Figure 314: Addiction Severity Index (ASI-6): alcohol composite score

| | gender re | esponsiv | e TC | stan | idard 1 | TC | | Mean Difference | Mean Difference |
|---------------------------------------------------|-----------|----------|-------|------|---------|-------|--------|---------------------|-----------------------------------------------------------|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI |
| Messina 2010 | 0.03 | 0.08 | 60 | 0.07 | 0.14 | 55 | 100.0% | -0.04 [-0.08, 0.00] | |
| Total (95% CI) | | | 60 | | | 55 | 100.0% | -0.04 [-0.08, 0.00] | |
| Heterogeneity: Not ag Test for overall effect: | | = 0.06) | | | | | | | -4 -2 0 2 4 Favours gender respon. TC Favours standard TC |

Figure 315: Addiction Severity Index (ASI-6): psychological composite score




Figure 316: Addiction Severity Index (ASI-6): drug composite score




Figure 317: Addiction Severity Index (ASI-6): family composite score




Figure 318: Participated in after-care upon release

| | gender responsiv | e TC | standar | d TC | | Risk Ratio | | Risk | Ratio | |
|--------------------------------------------------|------------------|-------|---------|-------|--------|---------------------|------|----------------------------|---------------------------|----------------|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | | M-H, Rand | om, 95% CI | |
| Messina 2010 | 28 | 60 | 30 | 55 | 100.0% | 0.86 [0.60, 1.23] | | - | - | |
| Total (95% CI) | | 60 | | 55 | 100.0% | 0.86 [0.60, 1.23] | | • | - | |
| Total events | 28 | | 30 | | | | | | | |
| Heterogeneity: Not ap Test for overall effect | • • | | | | | | 0.01 | 0.1 Favours standard TC | 10 Favours gender-resi | 100 pon. TC |

Figure 319: Months spent in after-care




Figure 320: Disciplinary removal from first residential placement post-release




Figure 321: Re-incarceration (12 month follow-up)




Figure 322: Voluntarily dropped out from first residential placement post-release





Figure 323: Months until re-incarceration



0.7.14.6 Gender-specific therapeutic community versus psychoeducation

Figure 324: Beck Depression Inventory (BDI) total score at post-treatment

| | theraper | rtic comm | unity | CBT pay | choeduc | ation | | Mean Difference | | Mean D | ufference | | |
|---------------------------------------------------|--------------------------|-----------|-------|---------|---------|-------|--------|----------------------|---------------|----------------------------|-------------|------------|----|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | | IV, Rando | om, 95% CI | | |
| Backs 2008 | 11.84 | 11.53 | 163 | 14.48 | 12.11 | 151 | 100.0% | -2.64 [-5.26, -0.02] | | - | | | |
| Total (95% CI) | | | 163 | | | 151 | 100.0% | -2.64 [-5.26, -0.02] | | | | | |
| Heterogeneity: Not ap Test for overall effect. | The second second second | = 0.05) | | | | | | | -10 Favous | -5 rs therapeutic comm. | Favours CB1 | f psychoed | 10 |

Figure 325: Brief Symptom Inventory (BSI) total score at post-treatment




Figure 326: Post-traumatic Symptom Severity Scale (PSS) at post-treatment





Figure 327: Self-reported criminal activity (Any)








Figure 329: Self-reported criminal activity (Sexual)

| | therapeutic comm | unity | CBT psychoedu | cation | | Risk Ratio | Risk Ratio | |
|-------------------------|------------------|-------|---------------|--------|--------|---------------------|------------------------------------------------|-----|
| Study or Subgroup | Events | Total | Events | Total | Weight | M.H. Random, 95% CI | M-H, Random, 95% CI | |
| Sacks 2008 | 3 | 163 | 8 | 151 | 100.0% | 0.35 (0.09, 1.29) | | |
| Total (95% CI) | | 163 | | 151 | 100.0% | 0.35 [0.09, 1.29] | | |
| Total events | 3 | | 8 | | | | 0 00 00 | |
| Heterogeneity: Not ap | opticable | | | | | | 0.01 0.1 10 | 100 |
| Test for overall effect | Z=1.58 (P=0.11) | | | | | | Favours therapeutic comm. Favours CBT psychoed | |

Figure 330: Receiving substance abuse treatment at follow-up

| | therapeutic con | imunity | CBT psychoed | ucation | | Risk Ratio | | Risk Rat | tio | |
|-------------------------|--------------------|---------|---------------------|---------|--------|--------------------|------|--------------------------|--------------------|-----|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Fixed, 95% CI | | M-H, Fixed, 9 | 95% CI | |
| Sacks 2008 | 109 | 163 | 118 | 151 | 100.0% | 0.86 (0.75, 0.98) | | | | |
| Total (95% CI) | | 163 | | 151 | 100.0% | 0.86 [0.75, 0.98] | | • | | |
| Total events | 109 | | 118 | | | | | 572 | | |
| Heterogeneity: Not as | pplicable | | | | | | 0.01 | 01 | 10 | 100 |
| Test for overall effect | Z = 2.23 (P = 0.03 |): | | | | | 0.01 | Favours CBT psychoed. Fa | avours therapeutic | |

Figure 331: Receiving mental health treatment at follow-up





Figure 332: Alcohol use at follow-up








Figure 334: Self-reported drug use




Figure 335: Re-arrest at follow-up




Figure 336: Re-incarceration at follow-up

| | therapeutic comm | nunity | CBT psychoed | ucation | | Risk Ratio | Risk | Ratio | |
|------------------------------------------------------|------------------|--------|--------------|---------|--------|---------------------|---------------------------------------|----------------------|-----|
| Study or Subgroup | Events | Total | Events | Total | Weight | M.H. Random, 95% CI | M.H. Rand | om, 95% CI | |
| Sacks 2012a | 59 | 257 | 59 | 211 | 100.0% | 0.82 (0.60, 1.12) | | on received | |
| Total (95% CI) | | 257 | | 211 | 100.0% | 0.82 [0.60, 1.12] | • | | |
| Total events | 59 | | 59 | | | | v v | 10 | |
| Heterogeneity: Not app Test for overall effect: Z | | | | | | | 0.01 0.1 Favours therapeutic comm. | Favours CBT esychoed | 100 |

0.7.14.7 Re-entry modified therapeutic community versus treatment as usual

Figure 337: Re-incarceration at 12-month follow-up




Figure 338: Criminal activity



Figure 339: Alcohol/drug offences

